Tan Ki-Wei, Griffiths Christopher E M
a Dermatology Centre, Manchester Academic Health Science Centre, Salford Royal Hospital , University of Manchester, Manchester , UK.
b Department of Dermatology , Changi General Hospital , Singapore.
Expert Opin Pharmacother. 2016;17(1):79-92. doi: 10.1517/14656566.2016.1109636. Epub 2015 Nov 7.
The immunopathogenesis of psoriasis has led to the discovery and development of several promising treatment options for psoriasis, including those that target the IL-17 and IL-23 pathways as well as small molecules that act on intracellular signaling pathways including the Janus kinase inhibitor and phosphodiesterase-4 inhibitor. Studies have demonstrated efficacy although long-term risks are not fully known. This review looks at novel systemic therapies for psoriasis that have emerged recently.
Systemic treatments for psoriasis that are in the late phase of development were reviewed, with the main focus on the efficacy and adverse effects of individual treatments.
The future of psoriasis treatment is likely to be based on clinical, genetic and immune biomarkers that will individualize treatment and may potentially optimize disease outcome.
银屑病的免疫发病机制促使人们发现并开发了几种有前景的银屑病治疗方案，包括针对白细胞介素-17和白细胞介素-23通路的药物，以及作用于细胞内信号通路的小分子药物，如 Janus 激酶抑制剂和磷酸二酯酶-4 抑制剂。研究已证明这些药物具有疗效，尽管长期风险尚不完全清楚。本综述着眼于近期出现的新型银屑病全身治疗方法。
对处于研发后期的银屑病全身治疗方法进行了综述，主要关注每种治疗方法的疗效和不良反应。
银屑病治疗的未来可能基于临床、基因和免疫生物标志物，这些标志物将实现个体化治疗，并可能优化疾病治疗效果。
